Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko,Jingjing Jiang,Tanner C. Dalton,Alvaro Curiel-Garcia,A. Cole Edwards,Yingyun Wang,Bianca Lee,Margo Orlen,Sha Tian,Clint A. Stalnecker,Kristina Drizyte-Miller,Marie Menard,Julien Dilly,Stephen A. Sastra,Carmine F. Palermo,Marie C. Hasselluhn,Amanda R. Decker-Farrell,Stephanie Chang,Lingyan Jiang,Xing Wei,Yu C. Yang,Ciara Helland,Haley Courtney,Yevgeniy Gindin,Karl Muonio,Ruiping Zhao,Samantha B. Kemp,Cynthia Clendenin,Rina Sor,William P. Vostrejs,Priya S. Hibshman,Amber M. Amparo,Connor Hennessey,Matthew G. Rees,Melissa M. Ronan,Jennifer A. Roth,Jens Brodbeck,Lorenzo Tomassoni,Basil Bakir,Nicholas D. Socci,Laura E. Herring,Natalie K. Barker,Junning Wang,James M. Cleary,Brian M. Wolpin,John A. Chabot,Michael D. Kluger,Gulam A. Manji,Kenneth Y. Tsai,Miroslav Sekulic,Stephen M. Lagana,Andrea Califano,Elsa Quintana,Zhengping Wang,Jacqueline A. M. Smith,Matthew Holderfield,David Wildes,Scott W. Lowe,Michael A. Badgley,Andrew J. Aguirre,Robert H. Vonderheide,Ben Z. Stanger,Timour Baslan,Channing J. Der,Mallika Singh,Kenneth P. Olive
DOI: https://doi.org/10.1038/s41586-024-07379-z
IF: 64.8
2024-04-09
Nature
Abstract:Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations 1,2 . RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants (RAS(ON) multi-selective) 3 . As >90% of human pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in KRAS 4 , we assessed the therapeutic potential of the RAS(ON) multi-selective inhibitor RMC-7977 in a comprehensive range of PDAC models. We observed broad and pronounced anti-tumor activity across models following direct RAS inhibition at exposures that were well-tolerated in vivo . Pharmacological analyses revealed divergent responses to RMC-7977 in tumor versus normal tissues. Treated tumors exhibited waves of apoptosis along with sustained proliferative arrest whereas normal tissues underwent only transient decreases in proliferation, with no evidence of apoptosis. In the autochthonous KPC model, RMC-7977 treatment resulted in a profound extension of survival followed by on-treatment relapse. Analysis of relapsed tumors identified Myc copy number gain as a prevalent candidate resistance mechanism, which could be overcome by combinatorial TEAD inhibition in vitro . Together, these data establish a strong preclinical rationale for the use of broad-spectrum RAS-GTP inhibition in the setting of PDAC and identify a promising candidate combination therapeutic regimen to overcome monotherapy resistance.
multidisciplinary sciences